Wnt/beta-catenin signaling and small molecule inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 634-664

  Voronkov, Andrey ^a   Krauss, Stefan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Drug discovery; Small molecule inhibitors; Stem cells; Wnt; catenin

Indexed keywords

2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] 6 METHYLPYRIMIDIN 4(3H) ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BETA CATENIN; BOSUTINIB; CAMBINOL; FILIPIN; IC 261; ICG 001; IMATINIB; IWP 1; IWP 2; IWR 1; J01 017A; JW 55; JW 74; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICLOSAMIDE; NSC 668036; OKADAIC ACID; PF 670462; PNU 74654; PROTEIN INHIBITOR; PYRIMIDINE DERIVATIVE; SULINDAC; TAUTOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; XAV 939;

ARTICLE; CELL FUNCTION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHROMATIN; CYTOPLASM; DEGENERATIVE DISEASE; DRUG STRUCTURE; EMBRYO DEVELOPMENT; ENZYME RELEASE; HUMAN; NEOPLASM; NONHUMAN; NUCLEUS ACCUMBENS; PORCUPINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION REGULATION;

EID: 84876716657     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804581837     Document Type: Article

References (479)

1. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31(1): 99-109.
2. Baker NE. Molecular cloning of sequences from wingless, a segment polarity gene in Drosophila: the spatial distribution of a transcript in embryos. EMBO J 1987; 6(6): 1765-1773.
3. McMahon AP, Moon RT. Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. Cell 1989; 58(6): 1075-1084.
4. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
5. Cadigan KM, Peifer M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol 2009; 1(2): a002881.
6. van Amerongen R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136(19): 3205-3214.
7. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17(1): 9-26.
8. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127(3): 469-480.
9. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17(1): 45-51.
10. Clevers H, Nusse R. Wnt/α-catenin signaling and disease. Cell 2012; 149(6): 1192-1205.
11. Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012; 31(12): 2737-2746.
12. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382(6592): 638-642.
13. Molenaar M, van de Wetering M., Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996; 86(3): 391-399.
14. van de Wetering M., Sancho E, Verweij C, de LW, Oving I, Hurlstone A et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111(2): 241-250.
15. Xu W, Kimelman D. Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 2007; 120(Pt 19): 3337-3344.
16. Coates JC. Armadillo repeat proteins: beyond the animal kingdom. Trends Cell Biol 2003; 13(9): 463-471.
17. Tewari R, Bailes E, Bunting KA, Coates JC. Armadillo-repeat protein functions: questions for little creatures. Trends Cell Biol 2010; 20(8): 470-481.
18. Huber AH, Nelson WJ, Weis WI. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell 1997; 90(5): 871-882.
19. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda) 2007; 22: 303-309.
20. Verheyen EM, Gottardi CJ. Regulation of Wnt/beta-catenin signaling by protein kinases. Dev Dyn 2010; 239(1): 34-44.
21. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10(12): 1443-1454.
22. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108(6): 837-847.
23. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K et al. An F-box protein, FWD1, mediates ubiquitindependent proteolysis of beta-catenin. EMBO J 1999; 18(9): 2401-2410.
24. Xing Y, Clements WK, Kimelman D, Xu W. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the betacatenin destruction complex. Genes Dev 2003; 17(22): 2753-2764.
25. Hart M, Concordet JP, Lassot I, Albert I, del los SR, Durand H et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9(4): 207-210.
26. van Noort M., van de Wetering M., Clevers H. Identification of two novel regulated serines in the N terminus of beta-catenin. Exp Cell Res 2002; 276(2): 264-272.
27. van Noort M., Meeldijk J., van der Zee R., Destree O, Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 2002; 277(20): 17901-17905.
28. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24(3): 245-250.
29. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000; 28(4): 443-453.
30. Dahmen RP, Koch A, Denkhaus D, Tonn JC, Sorensen N, Berthold F et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61(19): 7039-7043.
31. Clevers H. Axin and hepatocellular carcinomas. Nat Genet 2000; 24(3): 206-208.
32. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000; 26(2): 146-147.
33. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of betacatenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61(22): 8247-8255.
34. Parveen N, Hussain MU, Pandith AA, Mudassar S. Diversity of axin in signaling pathways and its relation to colorectal cancer. Med Oncol 2011; 28 Suppl 1: S259-S267.
35. Luo W, Lin SC. Axin: a master scaffold for multiple signaling pathways. Neurosignals 2004; 13(3): 99-113.
36. Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003; 1(1): E10.
37. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461(7264): 614-620.
38. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5(2): 100-107.
39. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 2011; 71(1): 197-205.
40. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012; 72(11): 2822-2832.
41. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280(5363): 596-599.
42. von Kries JP, Winbeck G, Asbrand C, Schwarz-Romond T, Sochnikova N, Dell'Oro A et al. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 2000; 7(9): 800-807.
43. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22(4): 1184-1193.
44. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002; 277(24): 21657-21665.
45. Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a selfbinding domain. J Biol Chem 1999; 274(6): 3439-3445.
46. Fiedler M, Mendoza-Topaz C, Rutherford TJ, Mieszczanek J, Bienz M. Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating betacatenin. Proc Natl Acad Sci U S A 2011; 108(5): 1937-1942.
47. Cliffe A, Hamada F, Bienz M. A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 2003; 13(11): 960-966.
48. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y et al. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol 2007; 14(6): 484-492.
49. Luo W, Zou H, Jin L, Lin S, Li Q, Ye Z et al. Axin contains three separable domains that confer intramolecular, homodimeric, and heterodimeric interactions involved in distinct functions. J Biol Chem 2005; 280(6): 5054-5060.
50. Druey KM, Blumer KJ, Kang VH, Kehrl JH. Inhibition of Gprotein-mediated MAP kinase activation by a new mammalian gene family. Nature 1996; 379(6567): 742-746.
51. De Vries L., Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 2000; 40: 235-271.
52. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gsaxin-beta-catenin signaling axis. Science 2005; 310(5753): 1504-1510.
53. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Curr Biol 2005; 15(22): 1989-1997.
54. Egger-Adam D, Katanaev VL. The trimeric G protein Go inflicts a double impact on axin in the Wnt/frizzled signaling pathway. Dev Dyn 2010; 239(1): 168-183.
55. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17(5): 1371-1384.
56. Kodama S, Ikeda S, Asahara T, Kishida M, Kikuchi A. Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem 1999; 274(39): 27682-27688.
57. Morrone S, Cheng Z, Moon RT, Cong F, Xu W. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. Proc Natl Acad Sci U S A 2012; 109(5): 1500-1505.
58. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999; 274(16): 10681-10684.
59. Jho E, Lomvardas S, Costantini F. A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcfmediated gene expression. Biochem Biophys Res Commun 1999; 266(1): 28-35.
60. Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R et al. Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex. EMBO J 2007; 26(6): 1511-1521.
61. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999; 13(14): 1768-1773.
62. Strovel ET, Wu D, Sussman DJ. Protein phosphatase 2Calpha dephosphorylates axin and activates LEF-1-dependent transcription. J Biol Chem 2000; 275(4): 2399-2403.
63. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K et al. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol Cell 2008; 32(5): 652-661.
64. Ratcliffe MJ, Itoh K, Sokol SY. A positive role for the PP2A catalytic subunit in Wnt signal transduction. J Biol Chem 2000; 275(46): 35680-35683.
65. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999; 283(5410): 2089-2091.
66. Ikeda S, Kishida M, Matsuura Y, Usui H, Kikuchi A. GSK-3betadependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 2000; 19(4): 537-545.
67. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 2011; 13(5): 623-629.
68. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One 2011; 6(7): e22595.
69. Kim MJ, Chia IV, Costantini F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J 2008; 22(11): 3785-3794.
70. Kadoya T, Kishida S, Fukui A, Hinoi T, Michiue T, Asashima M et al. Inhibition of Wnt signaling pathway by a novel axin-binding protein. J Biol Chem 2000; 275(47): 37030-37037.
71. Kadoya T, Yamamoto H, Suzuki T, Yukita A, Fukui A, Michiue T et al. Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of beta-catenin. Mol Cell Biol 2002; 22(11): 3803-3819.
72. Yamamoto H, Ihara M, Matsuura Y, Kikuchi A. Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J 2003; 22(9): 2047-2059.
73. Cha B, Kim W, Kim YK, Hwang BN, Park SY, Yoon JW et al. Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling. Oncogene 2011; 30(20): 2379-2389.
74. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A 2004; 101(9): 2882-2887.
75. Kaplan DD, Meigs TE, Kelly P, Casey PJ. Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle. J Biol Chem 2004; 279(12): 10829-10832.
76. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1(1): 55-67.
77. Green RA, Wollman R, Kaplan KB. APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 2005; 16(10): 4609-4622.
78. Wakefield JG, Stephens DJ, Tavare JM. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J Cell Sci 2003; 116(Pt 4): 637-646.
79. Kim SM, Choi EJ, Song KJ, Kim S, Seo E, Jho EH et al. Axin localizes to mitotic spindles and centrosomes in mitotic cells. Exp Cell Res 2009; 315(6): 943-954.
80. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3-β control Smad3 protein stability and modulate TGF-beta signaling. Genes Dev 2008; 22(1): 106-120.
81. Zhang M, Wang M, Tan X, Li TF, Zhang YE, Chen D. Smad3 prevents beta-catenin degradation and facilitates beta-catenin nuclear translocation in chondrocytes. J Biol Chem 2010; 285(12): 8703-8710.
82. Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res 1997; 57(3): 488-494.
83. Fodde R., Edelmann W, Yang K, van Leeuwen C., Carlson C, Renault B et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 1994; 91(19): 8969-8973.
84. Tejpar S, Michils G, Denys H, Van Dam K., Nik SA, Jadidizadeh A et al. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg 2005; 68(1): 5-9.
85. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997; 1332(3): F127-F147.
86. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14(15): 1837-1851.
87. Rubinfeld B, Tice DA, Polakis P. Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon. J Biol Chem 2001; 276(42): 39037-39045.
88. Ha NC, Tonozuka T, Stamos JL, Choi HJ, Weis WI. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol Cell 2004; 15(4): 511-521.
89. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2(9): 653-660.
90. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000; 406(6799): 1009-1012.
91. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000; 1(6): 519-523.
92. Zhang F, White RL, Neufeld KL. Phosphorylation near nuclear localization signal regulates nuclear import of adenomatous polyposis coli protein. Proc Natl Acad Sci U S A 2000; 97(23): 12577-12582.
93. Galea MA, Eleftheriou A, Henderson BR. ARM domain-dependent nuclear import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of protein phosphatase 2A. J Biol Chem 2001; 276(49): 45833-45839.
94. Neufeld KL. Nuclear APC. Adv Exp Med Biol 2009; 656: 13-29.
95. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 1994; 127(6 Pt 2): 2061-2069.
96. Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 1994; 54(14): 3676-3681.
97. Su LK, Burrell M, Hill DE, Gyuris J, Brent R, Wiltshire R et al. APC binds to the novel protein EB1. Cancer Res 1995; 55(14): 2972-2977.
98. Matsumine A, Ogai A, Senda T, Okumura N, Satoh K, Baeg GH et al. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 1996; 272(5264): 1020-1023.
99. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107(2): 519-527.
100. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 2002; 81(5): 1073-1083.
101. Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Beurel E, Boissan M, Delelo R, Cadoret A et al. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 2002; 36(6): 1528-1536.
102. Goto H, Kawano K, Kobayashi I, Sakai H, Yanagisawa S. Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 2002; 38(6): 549-556.
103. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25(3): 329-337.
104. Osolodkin DI, Palyulin VA, Zefirov NS. Glycogen synthase kinase 3 as an anticancer drug target: Novel experimental findings and trends in the design of inhibitors. Curr Pharm Des 2013; 19(4): 665-79.
105. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006; 7(11): 1421-1434.
106. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007; 32(4-5): 577-595.
107. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156(6): 885-898.
108. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406(6791): 86-90.
109. Sutherland C. What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis 2011; 2011: 505607.
110. Blair K, Wray J, Smith A. The liberation of embryonic stem cells. PLoS Genet 2011; 7(4): e1002019.
111. Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett Jr. et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009; 12(11): 1390-1397.
112. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/betacatenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12(6): 957-971.
113. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 2009; 14: 1558-1570.
114. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009; 284(15): 9643-9647.
115. Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci U S A 1995; 92(18): 8498-8502.
116. Jiang J, Struhl G. Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature 1998; 391(6666): 493-496.
117. Marikawa Y, Elinson RP. beta-TrCP is a negative regulator of Wnt/beta-catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech Dev 1998; 77(1): 75-80.
118. Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999; 18(4): 849-854.
119. Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B, Ben-Ze'ev A. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene 2000; 19(16): 1992-2001.
120. Teuliere J, Faraldo MM, Shtutman M, Birchmeier W, Huelsken J, Thiery JP et al. beta-catenin-dependent and-independent effects of DeltaN-plakoglobin on epidermal growth and differentiation. Mol Cell Biol 2004; 24(19): 8649-8661.
121. ter Haar E., Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 2001; 8(7): 593-596.
122. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320(5876): 667-670.
123. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377(Pt 1): 249-255.
124. Yost C, Farr GH, III, Pierce SB, Ferkey DM, Chen MM, Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 1998; 93(6): 1031-1041.
125. Li L, Yuan H, Weaver CD, Mao J, Farr GH, III, Sussman DJ et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999; 18(15): 4233-4240.
126. Freemantle SJ, Portland HB, Ewings K, Dmitrovsky F, DiPetrillo K, Spinella MJ et al. Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene 2002; 291(1-2): 17-27.
127. Wang Y, Liu S, Zhu H, Zhang W, Zhang G, Zhou X et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer 2008; 123(3): 561-568.
128. Guo G, Liu B, Zhong C, Zhang X, Mao X, Wang P et al. FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas. Med Oncol 2011; 28(1): 1-6.
129. Guo G, Mao X, Wang P, Liu B, Zhang X, Jiang X et al. The expression profile of FRAT1 in human gliomas. Brain Res 2010; 1320: 152-158.
130. Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan CF et al. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch 2011; 459(3): 255-263.
131. van Amerongen R., Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene 2010; 29(1): 93-104.
132. Flugel D, Gorlach A, Michiels C, Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 2007; 27(9): 3253-3265.
133. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6(10): 931-940.
134. Hernandez F, Nido JD, Avila J, Villanueva N. GSK3 inhibitors and disease. Mini Rev Med Chem 2009; 9(9): 1024-1029.
135. Garcia I, Fall Y, Gomez G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr Pharm Des 2010; 16(24): 2666-2675.
136. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003; 305(3): 974-980.
137. Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci 2008; 121(Pt 21): 3598-3607.
138. Anand P, Shenoy R, Palmer JE, Baines AJ, Lai RY, Robertson J et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011; 15(10): 1040-1048.
139. Xing L, Devadas B, Devraj RV, Selness SR, Shieh H, Walker JK et al. Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate. ChemMed-Chem 2012; 7(2): 273-280.
140. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADPribose) polymerase at human telomeres. Science 1998; 282(5393): 1484-1487.
141. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 2008; 90(1): 83-92.
142. Morrone S, Cheng Z, Moon RT, Cong F, Xu W. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. Proc Natl Acad Sci U S A 2012; 109(5): 1500-1505.
143. Kim CA, Phillips ML, Kim W, Gingery M, Tran HH, Robinson MA et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J 2001; 20(15): 4173-4182.
144. Kim CA, Gingery M, Pilpa RM, Bowie JU. The SAM domain of polyhomeotic forms a helical polymer. Nat Struct Biol 2002; 9(6): 453-457.
145. De Rycker M., Price CM. Tankyrase polymerization is controlled by its sterile alpha motif and poly(ADP-ribose) polymerase domains. Mol Cell Biol 2004; 24(22): 9802-9812.
146. Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011; 147(6): 1340-1354.
147. Slade D, Dunstan MS, Barkauskaite E, Weston R, Lafite P, Dixon N et al. The structure and catalytic mechanism of a poly(ADPribose) glycohydrolase. Nature 2011; 477(7366): 616-620.
148. Okita N, Ashizawa D, Ohta R, Abe H, Tanuma S. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose). Biochem Biophys Res Commun 2010; 392(4): 485-489.
149. Dregalla RC, Zhou J, Idate RR, Battaglia CL, Liber HL, Bailey SM. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany NY) 2010; 2(10): 691-708.
150. Wang Z, Michaud GA, Cheng Z, Zhang Y, Hinds TR, Fan E et al. Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADPribosyl) ation-dependent ubiquitination. Genes Dev 2012; 26(3): 235-240.
151. Ha GH, Kim HS, Go H, Lee H, Seimiya H, Chung DH et al. Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation. Cell Death Differ 2012; 19(2): 321-332.
152. Kikuchi K, Niikura Y, Kitagawa K, Kikuchi A. Dishevelled, a Wnt signalling component, is involved in mitotic progression in cooperation with Plk1. EMBO J 2010; 29(20): 3470-3483.
153. Chi NW, Lodish HF. Tankyrase is a golgi-associated mitogenactivated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J Biol Chem 2000; 275(49): 38437-38444.
154. Waters SB, D'Auria M, Martin SS, Nguyen C, Kozma LM, Luskey KL. The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes. J Biol Chem 1997; 272(37): 23323-23327.
155. Sbodio JI, Chi NW. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. J Biol Chem 2002; 277(35): 31887-31892.
156. Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J et al. Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene 2010; 29(49): 6418-6427.
157. Yeh TY, Meyer TN, Schwesinger C, Tsun ZY, Lee RM, Chi NW. Tankyrase recruitment to the lateral membrane in polarized epithelial cells: regulation by cell-cell contact and protein poly(ADPribosyl) ation. Biochem J 2006; 399(3): 415-425.
158. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460(7251): 66-72.
159. Gat U, DasGupta R, Degenstein L, Fuchs E. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated betacatenin in skin. Cell 1998; 95(5): 605-614.
160. Van Mater D., Kolligs FT, Dlugosz AA, Fearon ER. Transient activation of beta-catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev 2003; 17(10): 1219-1224.
161. Lo Celso C., Prowse DM, Watt FM. Transient activation of betacatenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 2004; 131(8): 1787-1799.
162. Millar SE. Cell biology: The not-so-odd couple. Nature 2009; 460(7251): 44-45.
163. Ulsamer A, Wei Y, Kim KK, Tan K, Wheeler S, Xi Y et al. Axin pathway activity regulates in vivo pY654-beta-catenin accumulation and pulmonary fibrosis. J Biol Chem 2012; 287(7): 5164-5172.
164. Seto ES, Bellen HJ. Internalization is required for proper Wingless signaling in Drosophila melanogaster. J Cell Biol 2006; 173(1): 95-106.
165. Karlberg T, Markova N, Johansson I, Hammarstrom M, Schutz P, Weigelt J et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J Med Chem 2010; 53(14): 5352-5355.
166. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012; 30(3): 283-288.
167. Narwal M, Fallarero A, Vuorela P, Lehtio L. Homogeneous screening assay for human tankyrase. J Biomol Screen 2012; 17(5): 593-604.
168. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012; 55(3): 1127-1136.
169. Gunaydin H, Gu Y, Huang X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS One 2012; 7(3): e33740.
170. Kirby CA, Cheung A, Fazal A, Shultz MD, Stams T. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012; 68(Pt 2): 115-118.
171. Dani N, Barbosa AJ, Del RA, Di GM. ADP-Ribosylated Proteins as Old and New Drug Targets for Anticancer Therapy: the Example of ARF6. Curr Pharm Des 2012.
172. Komekado H, Yamamoto H, Chiba T, Kikuchi A. Glycosylation and palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes Cells 2007; 12(4): 521-534.
173. Smolich BD, McMahon JA, McMahon AP, Papkoff J. Wnt family proteins are secreted and associated with the cell surface. Mol Biol Cell 1993; 4(12): 1267-1275.
174. Yan Q, Lennarz WJ. Oligosaccharyltransferase: a complex multisubunit enzyme of the endoplasmic reticulum. Biochem Biophys Res Commun 1999; 266(3): 684-689.
175. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423(6938): 448-452.
176. Buechling T, Boutros M. Wnt signaling signaling at and above the receptor level. Curr Top Dev Biol 2011; 97: 21-53.
177. Takada R, Satomi Y, Kurata T, Ueno N, Norioka S, Kondoh H et al. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 2006; 11(6): 791-801.
178. Mason JO, Kitajewski J, Varmus HE. Mutational analysis of mouse Wnt-1 identifies two temperature-sensitive alleles and attributes of Wnt-1 protein essential for transformation of a mammary cell line. Mol Biol Cell 1992; 3(5): 521-533.
179. Franch-Marro X, Wendler F, Griffith J, Maurice MM, Vincent JP. In vivo role of lipid adducts on Wingless. J Cell Sci 2008; 121(Pt 10): 1587-1592.
180. Port F, Basler K. Wnt trafficking: new insights into Wnt maturation, secretion and spreading. Traffic 2010; 11(10): 1265-1271.
181. Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell 2006; 125(3): 509-522.
182. Bartscherer K, Pelte N, Ingelfinger D, Boutros M. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell 2006; 125(3): 523-533.
183. Goodman RM, Thombre S, Firtina Z, Gray D, Betts D, Roebuck J et al. Sprinter: a novel transmembrane protein required for Wg secretion and signaling. Development 2006; 133(24): 4901-4911.
184. Adell T, Salo E, Boutros M, Bartscherer K. Smed-Evi/Wntless is required for beta-catenin-dependent and-independent processes during planarian regeneration. Development 2009; 136(6): 905-910.
185. Coombs GS, Yu J, Canning CA, Veltri CA, Covey TM, Cheong JK et al. WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. J Cell Sci 2010; 123(Pt 19): 3357-3367.
186. Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W. Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc Natl Acad Sci U S A 2009; 106(44): 18598-18603.
187. Yu HM, Jin Y, Fu J, Hsu W. Expression of Gpr177, a Wnt trafficking regulator, in mouse embryogenesis. Dev Dyn 2010; 239(7): 2102-2109.
188. Carpenter AC, Rao S, Wells JM, Campbell K, Lang RA. Generation of mice with a conditional null allele for Wntless. Genesis 2010; 48(9): 554-558.
189. Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, Sharma YV et al. The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi network. Dev Cell 2008; 14(1): 120-131.
190. Niehrs C, Boutros M. Trafficking, acidification, and growth factor signaling. Sci Signal 2010; 3(134): e26.
191. Tanaka K, Kitagawa Y, Kadowaki T. Drosophila segment polarity gene product porcupine stimulates the posttranslational Nglycosylation of wingless in the endoplasmic reticulum. J Biol Chem 2002; 277(15): 12816-12823.
192. Zhai L, Chaturvedi D, Cumberledge S. Drosophila wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine. J Biol Chem 2004; 279(32): 33220-33227.
193. Zoltewicz JS, Ashique AM, Choe Y, Lee G, Taylor S, Phamluong K et al. Wnt signaling is regulated by endoplasmic reticulum retention. PLoS One 2009; 4(7): e6191.
194. Dodge ME, Moon J, Tuladhar R, Lu J, Jacob LS, Zhang LS et al. Diverse chemical scaffolds support direct inhibition of the membrane bound O-acyltransferase Porcupine. J Biol Chem 2012; 287(27): 23246.
195. Zecca M, Basler K, Struhl G. Direct and long-range action of a wingless morphogen gradient. Cell 1996; 87(5): 833-844.
196. Fuerer C, Habib SJ, Nusse R. A study on the interactions between heparan sulfate proteoglycans and Wnt proteins. Dev Dyn 2010; 239(1): 184-190.
197. Panakova D, Sprong H, Marois E, Thiele C, Eaton S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 2005; 435(7038): 58-65.
198. Korkut C, Ataman B, Ramachandran P, Ashley J, Barria R, Gherbesi N et al. Trans-synaptic transmission of vesicular Wnt signals through Evi/Wntless. Cell 2009; 139(2): 393-404.
199. Yan D, Lin X. Shaping morphogen gradients by proteoglycans. Cold Spring Harb Perspect Biol 2009; 1(3): a002493.
200. Greco V, Hannus M, Eaton S. Argosomes: a potential vehicle for the spread of morphogens through epithelia. Cell 2001; 106(5): 633-645.
201. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010; 106(12): 1798-1806.
202. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 2007; 12(1): 113-127.
203. He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H. A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 1997; 275(5306): 1652-1654.
204. Tao Q, Yokota C, Puck H, Kofron M, Birsoy B, Yan D et al. Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos. Cell 2005; 120(6): 857-871.
205. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131(8): 1663-1677.
206. Li Y, Bu G. LRP5/6 in Wnt signaling and tumorigenesis. Future Oncol 2005; 1(5): 673-681.
207. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012; 31(12): 2670-84.
208. Vinson CR, Conover S, Adler PN. A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains. Nature 1989; 338(6212): 263-264.
209. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996; 382(6588): 225-230.
210. Tolwinski NS, Wehrli M, Rives A, Erdeniz N, DiNardo S, Wieschaus E. Wg/Wnt signal can be transmitted through arrow/ LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell 2003; 4(3): 407-418.
211. Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 2004; 131(20): 5103-5115.
212. Holmen SL, Robertson SA, Zylstra CR, Williams BO. Wntindependent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein. Biochem Biophys Res Commun 2005; 328(2): 533-539.
213. Caneparo L, Huang YL, Staudt N, Tada M, Ahrendt R, Kazanskaya O et al. Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt/beta catenin and Wnt/PCP activities, through interaction with the Dally-like homolog Knypek. Genes Dev 2007; 21(4): 465-480.
214. Bryja V, Andersson ER, Schambony A, Esner M, Bryjova L, Biris KK et al. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol Biol Cell 2009; 20(3): 924-936.
215. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407(6803): 530-535.
216. Cheyette BN, Waxman JS, Miller JR, Takemaru K, Sheldahl LC, Khlebtsova N et al. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. Dev Cell 2002; 2(4): 449-461.
217. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 2007; 316(5831): 1619-1622.
218. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A et al. LDLreceptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411(6835): 321-325.
219. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005; 438(7069): 867-872.
220. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z et al. A mechanism for Wnt coreceptor activation. Mol Cell 2004; 13(1): 149-156.
221. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R et al. A dualkinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005; 438(7069): 873-877.
222. Wu H, Symes K, Seldin DC, Dominguez I. Threonine 393 of betacatenin regulates interaction with Axin. J Cell Biochem 2009; 108(1): 52-63.
223. Pan W, Choi SC, Wang H, Qin Y, Volpicelli-Daley L, Swan L et al. Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science 2008; 321(5894): 1350-1353.
224. Katanaev VL, Ponzielli R, Semeriva M, Tomlinson A. Trimeric G protein-dependent frizzled signaling in Drosophila. Cell 2005; 120(1): 111-122.
225. Katanaev VL, Tomlinson A. Dual roles for the trimeric G protein Go in asymmetric cell division in Drosophila. Proc Natl Acad Sci U S A 2006; 103(17): 6524-6529.
226. Katanaev VL, Tomlinson A. Multiple roles of a trimeric G protein in Drosophila cell polarization. Cell Cycle 2006; 5(21): 2464-2472.
227. Egger-Adam D, Katanaev VL. Trimeric G protein-dependent signaling by Frizzled receptors in animal development. Front Biosci 2008; 13: 4740-4755.
228. Katanaev VL. The Wnt/Frizzled GPCR signaling pathway. Biochemistry (Mosc) 2010; 75(12): 1428-1434.
229. Purvanov V, Koval A, Katanaev VL. A direct and functional interaction between Go and Rab5 during G protein-coupled receptor signaling. Sci Signal 2010; 3(136): ra65.
230. Del Valle-Perez B, Arques O, Vinyoles M, de Herreros AG, Dunach M. Coordinated action of CK1 isoforms in canonical Wnt signaling. Mol Cell Biol 2011; 31(14): 2877-2888.
231. Cselenyi CS, Jernigan KK, Tahinci E, Thorne CA, Lee LA, Lee E. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of beta-catenin. Proc Natl Acad Sci U S A 2008; 105(23): 8032-8037.
232. Cong F, Schweizer L, Varmus H. Casein kinase Iepsilon modulates the signaling specificities of dishevelled. Mol Cell Biol 2004; 24(5): 2000-2011.
233. Zhai L, Graves PR, Robinson LC, Italiano M, Culbertson MR, Rowles J et al. Casein kinase I gamma subfamily. Molecular cloning, expression, and characterization of three mammalian isoforms and complementation of defects in the Saccharomyces cerevisiae YCK genes. J Biol Chem 1995; 270(21): 12717-12724.
234. Swiatek W, Tsai IC, Klimowski L, Pepler A, Barnette J, Yost HJ et al. Regulation of casein kinase I epsilon activity by Wnt signaling. J Biol Chem 2004; 279(13): 13011-13017.
235. Liang J, Fu Y, Cruciat CM, Jia S, Wang Y, Tong Z et al. Transmembrane protein 198 promotes LRP6 phosphorylation and Wnt signaling activation. Mol Cell Biol 2011; 31(13): 2577-2590.
236. Niehrs C, Shen J. Regulation of Lrp6 phosphorylation. Cell Mol Life Sci 2010; 67(15): 2551-2562.
237. Cervenka I, Wolf J, Masek J, Krejci P, Wilcox WR, Kozubik A et al. Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6. Mol Cell Biol 2011; 31(1): 179-189.
238. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK et al. Receptor tyrosine kinases activate canonical WNT/betacatenin signaling via MAP kinase/LRP6 pathway and direct betacatenin phosphorylation. PLoS One 2012; 7(4): e35826.
239. Piao S, Lee SH, Kim H, Yum S, Stamos JL, Xu Y et al. Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS One 2008; 3(12): e4046.
240. Kofron M, Birsoy B, Houston D, Tao Q, Wylie C, Heasman J. Wnt11/beta-catenin signaling in both oocytes and early embryos acts through LRP6-mediated regulation of axin. Development 2007; 134(3): 503-513.
241. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010; 143(7): 1136-1148.
242. Blitzer JT, Nusse R. A critical role for endocytosis in Wnt signaling. BMC Cell Biol 2006; 7: 28.
243. Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 2006; 11(2): 213-223.
244. de Lau W., Barker N, Low TY, Koo BK, Li VS, Teunissen H et al. Lgr5 homologues associate with Wnt receptors and mediate Rspondin signalling. Nature 2011; 476(7360): 293-297.
245. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 2011; 108(28): 11452-11457.
246. Glinka A, Dolde C, Kirsch N, Huang YL, Kazanskaya O, Ingelfinger D et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. EMBO Rep 2011; 12(10): 1055-1061.
247. Romero G, Sneddon WB, Yang Y, Wheeler D, Blair HC, Friedman PA. Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis. J Biol Chem 2010; 285(19): 14756-14763.
248. Gensure RC, Gardella TJ, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005; 328(3): 666-678.
249. Barker N., Huch M, Kujala P, van de Wetering M., Snippert H.J., van Es J.H. et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010; 6(1): 25-36.
250. He B, Jablons DM. Wnt signaling in stem cells and lung cancer. Ernst Schering Found Symp Proc 2006; (5): 27-58.
251. Gurney A. Oncomed Pharmaceuticals Inc.; 2007. METHODS FOR DIAGNOSING AND TREATING CANCER(FR) COMPOSITIONS ET PROCÉDÉS DE DIAGNOSTIC ET DE TRAITEMENT DU CANCER. 2012. Patent WO2007142711.
252. Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005; 24(41): 6201-6212.
253. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009; 48(43): 10267-10274.
254. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt coreceptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS One 2011; 6(12): e29290.
255. Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 2012; 31(4): 178-84.
256. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 2011; 71(12): 4172-4182.
257. Wharton KA, Jr. Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol 2003; 253(1): 1-17.
258. Metcalfe C, Mendoza-Topaz C, Mieszczanek J, Bienz M. Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization. J Cell Sci 2010; 123(Pt 9): 1588-1599.
259. Liu YT, Dan QJ, Wang J, Feng Y, Chen L, Liang J et al. Molecular basis of Wnt activation via the DIX domain protein Ccd1. J Biol Chem 2011; 286(10): 8597-8608.
260. Schwarz-Romond T, Merrifield C, Nichols BJ, Bienz M. The Wnt signalling effector Dishevelled forms dynamic protein assemblies rather than stable associations with cytoplasmic vesicles. J Cell Sci 2005; 118(Pt 22): 5269-5277.
261. Smalley MJ, Signoret N, Robertson D, Tilley A, Hann A, Ewan K et al. Dishevelled (Dvl-2) activates canonical Wnt signalling in the absence of cytoplasmic puncta. J Cell Sci 2005; 118(Pt 22): 5279-5289.
262. Simons M, Gault WJ, Gotthardt D, Rohatgi R, Klein TJ, Shao Y et al. Electrochemical cues regulate assembly of the Frizzled/ Dishevelled complex at the plasma membrane during planar epithelial polarization. Nat Cell Biol 2009; 11(3): 286-294.
263. Tauriello DV, Jordens I, Kirchner K, Slootstra JW, Kruitwagen T, Bouwman BA et al. Wnt/beta-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci U S A 2012; 109(14): E812-E820.
264. Punchihewa C, Ferreira AM, Cassell R, Rodrigues P, Fujii N. Sequence requirement and subtype specificity in the high-affinity interaction between human frizzled and dishevelled proteins. Protein Sci 2009; 18(5): 994-1002.
265. Zhang L, Gao X, Wen J, Ning Y, Chen YG. Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation. J Biol Chem 2006; 281(13): 8607-8612.
266. Chen H, Liu L, Ma B, Ma TM, Hou JJ, Xie GM et al. Protein kinase A-mediated 14-3-3 association impedes human Dapper1 to promote dishevelled degradation. J Biol Chem 2011; 286(17): 14870-14880.
267. Su Y, Zhang L, Gao X, Meng F, Wen J, Zhou H et al. The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling. FASEB J 2007; 21(3): 682-690.
268. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008; 13(6): 529-541.
269. Chen W, ten Berge D., Brown J, Ahn S, Hu LA, Miller WE et al. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 2003; 301(5638): 1391-1394.
270. Bryja V, Gradl D, Schambony A, Arenas E, Schulte G. Betaarrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci U S A 2007; 104(16): 6690-6695.
271. Yu A, Rual JF, Tamai K, Harada Y, Vidal M, He X et al. Association of Dishevelled with the clathrin AP-2 adaptor is required for Frizzled endocytosis and planar cell polarity signaling. Dev Cell 2007; 12(1): 129-141.
272. Klimowski LK, Garcia BA, Shabanowitz J, Hunt DF, Virshup DM. Site-specific casein kinase 1epsilon-dependent phosphorylation of Dishevelled modulates beta-catenin signaling. FEBS J 2006; 273(20): 4594-4602.
273. Bryja V, Schulte G, Arenas E. Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin. Cell Signal 2007; 19(3): 610-616.
274. Bernatik O, Ganji RS, Dijksterhuis JP, Konik P, Cervenka I, Polonio T et al. Sequential activation and inactivation of Dishevelled in the Wnt/beta-catenin pathway by casein kinases. J Biol Chem 2011; 286(12): 10396-10410.
275. Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY. Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. J Biol 2005; 4(1): 3.
276. Gao C, Cao W, Bao L, Zuo W, Xie G, Cai T et al. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol 2010; 12(8): 781-790.
277. Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP, Li L. Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 2008; 180(6): 1087-1100.
278. Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA et al. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A 2010; 107(20): 9216-9221.
279. Lai SL, Chien AJ, Moon RT. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res 2009; 19(5): 532-545.
280. Krylova O, Messenger MJ, Salinas PC. Dishevelled-1 regulates microtubule stability: a new function mediated by glycogen synthase kinase-3beta. J Cell Biol 2000; 151(1): 83-94.
281. Ciani L, Krylova O, Smalley MJ, Dale TC, Salinas PC. A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol 2004; 164(2): 243-253.
282. Salinas PC. Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway. Trends Cell Biol 2007; 17(7): 333-342.
283. Purro SA, Ciani L, Hoyos-Flight M, Stamatakou E, Siomou E, Salinas PC. Wnt regulates axon behavior through changes in microtubule growth directionality: a new role for adenomatous polyposis coli. J Neurosci 2008; 28(34): 8644-8654.
284. Lee HJ, Wang NX, Shi DL, Zheng JJ. Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. Angew Chem Int Ed Engl 2009; 48(35): 6448-6452.
285. Shan J, Zheng JJ. Optimizing Dvl PDZ domain inhibitor by exploring chemical space. J Comput Aided Mol Des 2009; 23(1): 37-47.
286. Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009; 284(24): 16256-16263.
287. Zhang Y, Appleton BA, Wiesmann C, Lau T, Costa M, Hannoush RN et al. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat Chem Biol 2009; 5(4): 217-219.
288. Shan J, Zhang X, Bao J, Cassell R, Zheng JJ. Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies. Chem Biol Drug Des 2012; 79(4): 376-383.
289. Shan J, Shi DL, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005; 44(47): 15495-15503.
290. Andersson ER. The role of endocytosis in activating and regulating signal transduction. Cell Mol Life Sci 2012; 69(11): 1755-1771.
291. Li Y, Lu W, King TD, Liu CC, Bijur GN, Bu G. Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation. PLoS One 2010; 5(6): e11014.
292. Gagliardi M, Piddini E, Vincent JP. Endocytosis: a positive or a negative influence on Wnt signalling? Traffic 2008; 9(1): 1-9.
293. Dubois L, Lecourtois M, Alexandre C, Hirst E, Vincent JP. Regulated endocytic routing modulates wingless signaling in Drosophila embryos. Cell 2001; 105(5): 613-624.
294. Zhang J, Barak LS, Winkler KE, Caron MG, Ferguson SS. A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. J Biol Chem 1997; 272(43): 27005-27014.
295. Chen W, Hu LA, Semenov MV, Yanagawa S, Kikuchi A, Lefkowitz RJ et al. beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc Natl Acad Sci U S A 2001; 98(26): 14889-14894.
296. Jiang Y, He X, Howe PH. Disabled-2 (Dab2) inhibits Wnt/betacatenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J 2012; 31(10): 2336-2349.
297. Yamamoto H, Sakane H, Yamamoto H, Michiue T, Kikuchi A. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of beta-catenin signaling. Dev Cell 2008; 15(1): 37-48.
298. Platta HW, Stenmark H. Endocytosis and signaling. Curr Opin Cell Biol 2011; 23(4): 393-403.
299. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004; 16(4): 415-421.
300. Simons M, Raposo G. Exosomes--vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009; 21(4): 575-581.
301. Schneider A, Simons M., Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 2012. DOI10.1007/s00441-012-1428-2.
302. Piddini E, Marshall F, Dubois L, Hirst E, Vincent JP. Arrow (LRP6) and Frizzled2 cooperate to degrade Wingless in Drosophila imaginal discs. Development 2005; 132(24): 5479-5489.
303. Hupalowska A, Miaczynska M. The new faces of endocytosis in signaling. Traffic 2012; 13(1): 9-18.
304. Hay E, Nouraud A, Marie PJ. N-cadherin negatively regulates osteoblast proliferation and survival by antagonizing Wnt, ERK and PI3K/Akt signalling. PLoS One 2009; 4(12): e8284.
305. Casagolda D, Del Valle-Perez B, Valls G, Lugilde E, Vinyoles M, Casado-Vela J et al. A p120-catenin-CK1epsilon complex regulates Wnt signaling. J Cell Sci 2010; 123(Pt 15): 2621-2631.
306. Dupre-Crochet S, Figueroa A, Hogan C, Ferber EC, Bialucha CU, Adams J et al. Casein kinase 1 is a novel negative regulator of Ecadherin-based cell-cell contacts. Mol Cell Biol 2007; 27(10): 3804-3816.
307. Greer YE, Rubin JS. Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a-dependent neurite outgrowth. J Cell Biol 2011; 192(6): 993-1004.
308. Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH et al. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. Oncogene 2011; 30(22): 2558-2569.
309. Park JI, Ji H, Jun S, Gu D, Hikasa H, Li L et al. Frodo links Dishevelled to the p120-catenin/Kaiso pathway: distinct catenin subfamilies promote Wnt signals. Dev Cell 2006; 11(5): 683-695.
310. Cox RT, Kirkpatrick C, Peifer M. Armadillo is required for adherens junction assembly, cell polarity, and morphogenesis during Drosophila embryogenesis. J Cell Biol 1996; 134(1): 133-148.
311. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16(1): 51-59.
312. Thiery JP. Cell adhesion in development: a complex signaling network. Curr Opin Genet Dev 2003; 13(4): 365-371.
313. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent betacatenin transcriptional activity. J Cell Biol 2001; 154(6): 1185-1196.
314. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 2001; 153(5): 1049-1060.
315. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and betacatenin/ LEF-1-mediated transactivation. J Cell Sci 1999; 112 (Pt 8): 1237-1245.
316. Brooke MA, Nitoiu D, Kelsell DP. Cell-cell connectivity: desmosomes and disease. J Pathol 2012; 226(2): 158-171.
317. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84(3): 345-357.
318. Yeaman C, Grindstaff KK, Nelson WJ. New perspectives on mechanisms involved in generating epithelial cell polarity. Physiol Rev 1999; 79(1): 73-98.
319. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004; 5(4): 261-270.
320. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13(23): 7003-7011.
321. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci 2008; 121(Pt 6): 727-735.
322. Hazan RB, Kang L, Whooley BP, Borgen PI. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 1997; 4(6): 399-411.
323. Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL. Vinculin is associated with the E-cadherin adhesion complex. J Biol Chem 1997; 272(51): 32448-32453.
324. Knudsen KA, Sauer C, Johnson KR, Wheelock MJ. Effect of Ncadherin misexpression by the mammary epithelium in mice. J Cell Biochem 2005; 95(6): 1093-1107.
325. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007; 67(7): 3106-3116.
326. Behrens J, Weidner KM, Frixen UH, Schipper JH, Sachs M, Arakaki N et al. The role of E-cadherin and scatter factor in tumor invasion and cell motility. EXS 1991; 59: 109-126.
327. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113(1): 173-185.
328. Nagar B, Overduin M, Ikura M, Rini JM. Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 1996; 380(6572): 360-364.
329. Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze'ev A. Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 1996; 133(1): 199-209.
330. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF et al. Dynamic and static interactions between p120 catenin and Ecadherin regulate the stability of cell-cell adhesion. Cell 2010; 141(1): 117-128.
331. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol 2003; 163(3): 525-534.
332. Xiao K, Allison DF, Buckley KM, Kottke MD, Vincent PA, Faundez V et al. Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. J Cell Biol 2003; 163(3): 535-545.
333. Kowalczyk AP, Reynolds AB. Protecting your tail: regulation of cadherin degradation by p120-catenin. Curr Opin Cell Biol 2004; 16(5): 522-527.
334. Ireton RC, Davis MA, van Hengel J., Mariner DJ, Barnes K, Thoreson MA et al. A novel role for p120 catenin in E-cadherin function. J Cell Biol 2002; 159(3): 465-476.
335. Reynolds AB. p120-catenin: Past and present. Biochim Biophys Acta 2007; 1773(1): 2-7.
336. Nagafuchi A, Takeichi M, Tsukita S. The 102 kd cadherinassociated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell 1991; 65(5): 849-857.
337. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251(5000): 1451-1455.
338. Gumbiner BM, McCrea PD. Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl 1993; 17: 155-158.
339. Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ. Deconstructing the cadherin-catenin-actin complex. Cell 2005; 123(5): 889-901.
340. Choi HJ, Gross JC, Pokutta S, Weis WI. Interactions of plakoglobin and beta-catenin with desmosomal cadherins: basis of selective exclusion of alpha-and beta-catenin from desmosomes. J Biol Chem 2009; 284(46): 31776-31788.
341. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001; 105(3): 391-402.
342. Pokutta S, Weis WI. Structure of the dimerization and beta-cateninbinding region of alpha-catenin. Mol Cell 2000; 5(3): 533-543.
343. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de HA et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-cateninalpha-catenin Interaction. Mol Cell Biol 2003; 23(7): 2287-2297.
344. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Y654 of beta-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of beta-catenin. Eur J Haematol 2012; 88(4): 314-320.
345. Piedra J, Martinez D, Castano J, Miravet S, Dunach M, de Herreros AG. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 2001; 276(23): 20436-20443.
346. van Veelen W., Le N.H., Helvensteijn W, Blonden L, Theeuwes M, Bakker ER et al. beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011; 60(9): 1204-1212.
347. Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005; 25(20): 9063-9072.
348. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281(15): 9971-9976.
349. Tian Q, Feetham MC, Tao WA, He XC, Li L, Aebersold R et al. Proteomic analysis identifies that 14-3-3zeta interacts with betacatenin and facilitates its activation by Akt. Proc Natl Acad Sci U S A 2004; 101(43): 15370-15375.
350. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G et al. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factorkappa B and beta-catenin. Oncogene 2005; 24(6): 1021-1031.
351. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007; 282(15): 11221-11229.
352. Roura S, Miravet S, Piedra J, Garcia de Herreros A., Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274(51): 36734-36740.
353. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002; 8(7): 2430-2436.
354. Genda T, Sakamoto M, Ichida T, Asakura H, Hirohashi S. Loss of cell-cell contact is induced by integrin-mediated cell-substratum adhesion in highly-motile and highly-metastatic hepatocellular carcinoma cells. Lab Invest 2000; 80(3): 387-394.
355. Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001; 61(8): 3508-3517.
356. Coluccia AM, Benati D, Dekhil H, De Filippo A., Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006; 66(4): 2279-2286.
357. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008; 7(5): 1185-1194.
358. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012; 18(4): 1092-1100.
359. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21(8): 1948-1956.
360. Serban G, Kouchi Z, Baki L, Georgakopoulos A, Litterst CM, Shioi J et al. Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability. J Biol Chem 2005; 280(43): 36007-36012.
361. Sanson B, White P, Vincent JP. Uncoupling cadherin-based adhesion from wingless signalling in Drosophila. Nature 1996; 383(6601): 627-630.
362. Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A, Geiger B. Inhibition of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A 1998; 95(26): 15339-15344.
363. Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R et al. Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 2008; 21(3): 271-281.
364. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS et al. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab 2009; 94(4): 1436-1442.
365. Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA et al. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2003; 278(2): 1372-1379.
366. Pan FY, Zhang SZ, Xu N, Meng FL, Zhang HX, Xue B et al. Betacatenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. Histochem Cell Biol 2010; 134(3): 285-295.
367. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996; 61(4): 514-523.
368. Aberle H, Schwartz H, Hoschuetzky H, Kemler R. Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin. J Biol Chem 1996; 271(3): 1520-1526.
369. Choi KH, Park MW, Lee SY, Jeon MY, Kim MY, Lee HK et al. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol Cancer Ther 2006; 5(9): 2428-2434.
370. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994; 127(5): 1375-1380.
371. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11(2): 162-171.
372. Denzel S, Maetzel D, Mack B, Eggert C, Barr G, Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009; 9: 402.
373. Blaschuk OW, Devemy E. Cadherins as novel targets for anticancer therapy. Eur J Pharmacol 2009; 625(1-3): 195-198.
374. Yarom N, Stewart D, Malik R, Wells J, Avruch L, Jonker DJ. Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors. Curr Clin Pharmacol 2012.
375. Iozzo MV. Proteoglycans: structure, biology and molecular interactions. Gallagher JTLM, editor. Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens. 27-59. 2000. New York, Marcel Dekker Inc. Ref Type: Generic
376. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003; 88(2): 408-417.
377. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15(1): 49-51.
378. Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12(2): 89-103.
379. Vermeulen L, de Sousa E Melo, van der Heijden M., Cameron K, de Jong J.H., Borovski T et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12(5): 468-476.
380. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62(7): 2064-2071.
381. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303(5663): 1483-1487.
382. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/ Met and beta-catenin/Wnt pathways. Eur J Cancer 2010; 46(9): 1679-1691.
383. Sharma M, Jamieson C, Johnson M, Molloy MP, Henderson BR. Specific armadillo repeat sequences facilitate beta-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358. J Biol Chem 2012; 287(2): 819-831.
384. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007; 21(12): 2476-2484.
385. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the betacatenin signaling activity. Cancer Lett 2003; 193(2): 161-170.
386. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63(21): 7345-7355.
387. Cianfrocca R, Tocci P, Spinella F, Di C, V, Bagnato A, Rosano L. The endothelin A receptor and epidermal growth factor receptor signaling converge on beta-catenin to promote ovarian cancer metastasis. Life Sci 2012; 91(13-14): 550-556.
388. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003; 3(1): 31-40.
389. Grotegut S., Von Schweinitz D., Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006; 25(15): 3534-3545.
390. Leroy P, Mostov KE. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell 2007; 18(5): 1943-1952.
391. Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol 2005; 8(4): 435-447.
392. Lickert H, Bauer A, Kemler R, Stappert J. Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. J Biol Chem 2000; 275(7): 5090-5095.
393. Du C, Jaggi M, Zhang C, Balaji KC. Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. Cancer Res 2009; 69(3): 1117-1124.
394. Li J, Sutter C, Parker DS, Blauwkamp T, Fang M, Cadigan KM. CBP/p300 are bimodal regulators of Wnt signaling. EMBO J 2007; 26(9): 2284-2294.
395. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996; 59(1): 3-10.
396. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene 2006; 25(57): 7492-7504.
397. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. J Cell Sci 2007; 120(Pt 3): 385-393.
398. Solberg N, Machon O, Machonova O, Krauss S. Mouse Tcf3 represses canonical Wnt signaling by either competing for betacatenin binding or through occupation of DNA-binding sites. Mol Cell Biochem 2012; 365(1-2): 53-63.
399. Van de Wetering M, Castrop J, Korinek V, Clevers H. Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. Mol Cell Biol 1996; 16(3): 745-752.
400. Brantjes H., Roose J, van de Wetering M., Clevers H. All Tcf HMG box transcription factors interact with Groucho-related corepressors. Nucleic Acids Res 2001; 29(7): 1410-1419.
401. Archbold HC, Yang YX, Chen L, Cadigan KM. How do they do Wnt they do?: regulation of transcription by the Wnt/beta-catenin pathway. Acta Physiol (Oxf) 2012; 204(1): 74-109.
402. Cadigan KM. TCFs and Wnt/beta-catenin signaling: more than one way to throw the switch. Curr Top Dev Biol 2012; 98: 1-34.
403. Daniels DL, Weis WI. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12(4): 364-371.
404. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ. Structure of a human Tcf4-beta-catenin complex. Nat Struct Biol 2001; 8(12): 1053-1057.
405. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Differential mechanisms of LEF/TCF family-dependent transcriptional activation by betacatenin and plakoglobin. Mol Cell Biol 2000; 20(12): 4238-4252.
406. Miravet S, Piedra J, Miro F, Itarte E, Garcia de Herreros A., Dunach M. The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin. J Biol Chem 2002; 277(3): 1884-1891.
407. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K et al. Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 2004; 23(4): 964-972.
408. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR et al. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000; 14(11): 1319-1331.
409. Karnovsky A, Klymkowsky MW. Anterior axis duplication in Xenopus induced by the over-expression of the cadherin-binding protein plakoglobin. Proc Natl Acad Sci U S A 1995; 92(10): 4522-4526.
410. Daniel JM, Spring CM, Crawford HC, Reynolds AB, Baig A. The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res 2002; 30(13): 2911-2919.
411. Wang HY, Wang YJ, Cui MJ, Gu CM, Yang LZ, Zhao Y et al. Hepatocyte growth factor-induced amelioration in renal interstitial fibrosis is associated with reduced expression of alpha-smooth muscle actin and transforming growth factor-beta1. Indian J Biochem Biophys 2011; 48(5): 308-315.
412. Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K et al. Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. Dev Cell 2005; 8(6): 843-854.
413. Spring CM, Kelly KF, O'Kelly I, Graham M, Crawford HC, Daniel JM. The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin/TCF target gene matrilysin. Exp Cell Res 2005; 305(2): 253-265.
414. Bauer A, Huber O, Kemler R. Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci U S A 1998; 95(25): 14787-14792.
415. Hecht A, Litterst CM, Huber O, Kemler R. Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro. J Biol Chem 1999; 274(25): 18017-18025.
416. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002; 109(1): 47-60.
417. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 2004; 6(7): 626-633.
418. Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT. Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature 2003; 422(6934): 905-909.
419. Li FQ, Mofunanya A, Harris K, Takemaru K. Chibby cooperates with 14-3-3 to regulate beta-catenin subcellular distribution and signaling activity. J Cell Biol 2008; 181(7): 1141-1154.
420. Chua EL, Young L, Wu WM, Turtle JR, Dong Q. Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics 2000; 69(3): 342-347.
421. Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP et al. TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res 2004; 64(8): 2766-2773.
422. Zhang C, Cho K, Huang Y, Lyons JP, Zhou X, Sinha K et al. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci U S A 2008; 105(19): 6936-6941.
423. Torres MA, Nelson WJ. Colocalization and redistribution of dishevelled and actin during Wnt-induced mesenchymal morphogenesis. J Cell Biol 2000; 149(7): 1433-1442.
424. Hammerlein A, Weiske J, Huber O. A second protein kinase CK1-mediated step negatively regulates Wnt signalling by disrupting the lymphocyte enhancer factor-1/beta-catenin complex. Cell Mol Life Sci 2005; 62(5): 606-618.
425. Wang S, Jones KA. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol 2006; 16(22): 2239-2244.
426. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010; 70(6): 2516-2527.
427. Sun J, Weis WI. Biochemical and structural characterization of beta-catenin interactions with nonphosphorylated and CK2-phosphorylated Lef-1. J Mol Biol 2011; 405(2): 519-530.
428. Ishitani T, Ninomiya-Tsuji J, Nagai S, Nishita M, Meneghini M, Barker N et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 1999; 399(6738): 798-802.
429. Ishitani T. Context-dependent dual and opposite roles of nemo-like kinase in the Wnt/beta-catenin signaling. Cell Cycle 2012; 11(9): 1743-1745.
430. Zeng YA, Verheyen EM. Nemo is an inducible antagonist of Wingless signaling during Drosophila wing development. Development 2004; 131(12): 2911-2920.
431. Ishitani T, Ninomiya-Tsuji J, Matsumoto K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol 2003; 23(4): 1379-1389.
432. Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M, Ishitani T. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J 2012; 31(8): 1904-1915.
433. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001; 15(23): 3088-3103.
434. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004; 101(34): 12682-12687.
435. Zhou B, Liu Y, Kahn M, Ann DK, Han A, Wang H et al. Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem 2012; 287(10): 7026-7038.
436. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16(12): 3153-3162.
437. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 2009; 4(12): e8294.
438. Schmidt M, Kim Y, Gast SM, Endo T, Lu D, Carson D et al. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 2011; 25(3): 325-333.
439. Jin G, Lu D, Yao S, Wu CC, Liu JX, Carson DA et al. Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival. Bioorg Med Chem Lett 2009; 19(3): 606-609.
440. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F et al. Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex. Cancer Cell 2004; 5(1): 91-102.
441. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5(12): 997-1014.
442. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2010; 126(10): 2426-2436.
443. Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S et al. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006; 64(1): 60-67.
444. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N et al. Structurebased discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. Biochemistry 2012; 51(2): 724-731.
445. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399(6733): 271-275.
446. Rubin JS, Bottaro DP. Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clin Cancer Res 2007; 13(16): 4660-4663.
447. Burrows N, Babur M, Resch J, Williams KJ, Brabant G. Hypoxiainducible factor in thyroid carcinoma. J Thyroid Res 2011; 96(12): E1934-1943.
448. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721-732.
449. Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling EJ et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab 2011; 96(12): E1934-E1943.
450. Kaidi A, Williams AC, Paraskeva C. Interaction between betacatenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007; 9(2): 210-217.
451. Mazumdar J, O'Brien WT, Johnson RS, LaManna JC, Chavez JC, Klein PS et al. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 2010; 12(10): 1007-1013.
452. Newton IP, Kenneth NS, Appleton PL, Nathke I, Rocha S. Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell 2010; 21(21): 3630-3638.
453. Kawabata A. Prostaglandin E2 and pain--an update. Biol Pharm Bull 2011; 34(8): 1170-1173.
454. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179(1-2): 56-65.
455. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9(1): 6-8.
456. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 2000; 97(22): 11960-11965.
457. Smartt HJ, Greenhough A, Ordonez-Moran P, Talero E, Cherry CA, Wallam CA et al. beta-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut 2011; 61(9):1306-1314.
458. Hsi LC, Angerman-Stewart J, Eling TE. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 1999; 20(11): 2045-2049.
459. George SJ. Wnt pathway: a new role in regulation of inflammation. Arterioscler Thromb Vasc Biol 2008; 28(3): 400-402.
460. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59(12): 1670-1679.
461. Brudvik KW, Paulsen JE, Aandahl EM, Roald B, Tasken K. Protein kinase A antagonist inhibits beta-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol Cancer 2011; 10: 149.
462. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1(3): 169-178.
463. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113(6): 685-700.
464. Liu W, Rui H, Wang J, Lin S, He Y, Chen M et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J 2006; 25(8): 1646-1658.
465. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389(6651): 622-626.
466. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6(6): 1365-1375.
467. Kim S, Jho EH. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem 2010; 285(47): 36420-36426.
468. Han G, Li AG, Liang YY, Owens P, He W, Lu S et al. Smad7-induced beta-catenin degradation alters epidermal appendage development. Dev Cell 2006; 11(3): 301-312.
469. Edlund S, Lee SY, Grimsby S, Zhang S, Aspenstrom P, Heldin CH et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005; 25(4): 1475-1488.
470. Tang Y, Liu Z, Zhao L, Clemens TL, Cao X. Smad7 stabilizes betacatenin binding to E-cadherin complex and promotes cell-cell adhesion. J Biol Chem 2008; 283(35): 23956-23963.
471. DiVito KA, Trabosh VA, Chen YS, Chen Y, Albanese C, Javelaud D et al. Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo. Pigment Cell Melanoma Res 2010; 23(6): 795-808.
472. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from betacatenin. Cell 2006; 127(1): 139-155.
473. Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, Wang Y et al. PDGF upregulates Mcl-1 through activation of α-catenin and HIF-1β-dependent signaling in human prostate cancer cells. PLoS One 2012; 7(1): e30764.
474. Dufourcq P, Descamps B, Tojais NF, Leroux L, Oses P, Daret D et al. Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation. Stem Cells 2008; 26(11): 2991-3001.
475. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V et al. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. Nat Cell Biol 2011; 13(10): 1244-1251.
476. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 2007; 3(1): 30-38.
477. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 2012; 72(16): 4154-64.
478. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S et al. Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18(6): 892-901.
479. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R. et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004; 90(1): 224-229.